| 566.89 -8.45 (-1.47%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 680.25 | 1-year : | 794.53 |
| Resists | First : | 582.4 | Second : | 680.25 |
| Pivot price | 565.5  |
|||
| Supports | First : | 548.53 |
Second : | 527.59 |
| MAs | MA(5) : | 569.63 |
MA(20) : | 565.91 |
| MA(100) : | 494.39 |
MA(250) : | 0 | |
| MACD | MACD : | 12.7 |
Signal : | 15.5 |
| %K %D | K(14,3) : | 72 |
D(3) : | 71.6 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 616 | Low : | 425 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ISRG ] has closed below upper band by 46.7%. Bollinger Bands are 32.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 577.3 - 580.04 | 580.04 - 582.61 |
| Low: | 562.31 - 565.51 | 565.51 - 568.52 |
| Close: | 570.14 - 575.12 | 575.12 - 579.79 |
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Mon, 08 Dec 2025
ISRG Stock Forms Golden Crossover: Will the Uptrend Continue? - Finviz
Mon, 08 Dec 2025
Vega Investment Solutions Sells 10,530 Shares of Intuitive Surgical, Inc. $ISRG - MarketBeat
Mon, 08 Dec 2025
Natixis Has $65.35 Million Stake in Intuitive Surgical, Inc. $ISRG - MarketBeat
Mon, 08 Dec 2025
Intuitive Surgical, Inc. $ISRG Shares Sold by SVB Wealth LLC - MarketBeat
Mon, 08 Dec 2025
Ossiam Has $27.44 Million Position in Intuitive Surgical, Inc. $ISRG - MarketBeat
Mon, 08 Dec 2025
Surgical Equipment & Consumables - Specialty Stocks Q3 Earnings: Intuitive Surgical (NASDAQ:ISRG) Best of the Bunch - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 355 (M) |
| Shares Float | 352 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 88.4 (%) |
| Shares Short | 7,450 (K) |
| Shares Short P.Month | 7,390 (K) |
| EPS | 7.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 47.7 |
| Profit Margin | 28.5 % |
| Operating Margin | 30.3 % |
| Return on Assets (ttm) | 9.5 % |
| Return on Equity (ttm) | 16.8 % |
| Qtrly Rev. Growth | 22.8 % |
| Gross Profit (p.s.) | 17.99 |
| Sales Per Share | 27.1 |
| EBITDA (p.s.) | 9.61 |
| Qtrly Earnings Growth | 25 % |
| Operating Cash Flow | 2,960 (M) |
| Levered Free Cash Flow | 1,970 (M) |
| PE Ratio | 74.86 |
| PEG Ratio | 0 |
| Price to Book value | 11.88 |
| Price to Sales | 20.9 |
| Price to Cash Flow | 67.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|